Table 1.
The ratios of organs to body weight during infection
| Week 1 | Week 2 | Week 3 | ||||
|---|---|---|---|---|---|---|
| Liver | Spleen | Liver | Spleen | Liver | Spleen | |
| Con | 48.15 ± 0.17 | 4.61 ± 0.99 | 48.61 ± 1.99 | 4.55 ± 1.12 | 47.87 ± 5.65 | 4.62 ± 0.41 |
| PL16 | 48.26 ± 0.18 | 3.54 ± 1.54 | 48.49 ± 1.88 | 3.44 ± 1.02 | 42.91 ± 5.32 | 3.61 ± 0.88 |
| TL16 | 54.35 ± 2.80 | 4.75 ± 0.86 | 52.65 ± 1.05 | 4.98 ± 1.50 | 46.56 ± 9.01 | 5.65 ± 0.81 |
| Mod | 58.18 ± 1.14** | 4.67 ± 1.78 | 56.18 ± 5.37** | 4.76 ± 1.83 | 51.77 ± 4.70 | 5.06 ± 0.97 |
The data is presented by ratio of organ to body weight by mean ± SD. (**, p < 0.05).
Groups are matched with experimental design in Method section. Con: the control group with orally administration of PBS. PL16: the protection group with administration of L16 strain before Staphylococcus aureus infection. TL16: the treatment group with administration of L16 strain after Staphylococcus aureus infection. Mod: murine model group with Staphylococcus aureus infection daily for 1 week.